Caterina Bigi1,2, Guido Bocci3. 1. Division of Pharmacology, Department of Clinical and Experimental Medicine, Scuola Medica, University of Pisa, Via Roma 55, 56126, Pisa, Italy. 2. Barking, Havering and Redbridge University Hospital, HNS Trust, London, UK. 3. Division of Pharmacology, Department of Clinical and Experimental Medicine, Scuola Medica, University of Pisa, Via Roma 55, 56126, Pisa, Italy. guido.bocci@med.unipi.it.
Abstract
PURPOSE: The reporting of suspected adverse drug reactions (ADRs) is starting to become routine to nurses. The aim of this review is to underline the role of clinical and community health nurses in pharmacovigilance and to promote their effective participation in ADR reporting in different countries and for patients of different ages. METHODS: The PubMed, Scopus and ISI Web of Science databases were searched for research articles published between January 1985 and April 2017 using the search items "pharmacovigilance" AND "nurse;" "adverse drug reaction report" AND "nurse;" "community health nurse" AND "adverse drug reaction." RESULTS: A total of 987 articles were identified using our search strategy, of which 180 articles remained over after the removal of duplicate articles. Of these 180 studies, upon full review we identified 24 which met the inclusion/exclusion criteria and included these in our review. ADR reports by clinical nurses in some countries are comparable in quality and number to those submitted by physicians or pharmacists. Data on ADRs reported by community nurses are currently not available. However, numerous publications emphasized the challenges faced by nurses in reporting ADRs and the need to include pharmacovigilance training in both clinical and community health nurse academic education. CONCLUSIONS: Nurses are central actors in pharmacovigilance activities, particularly in identifying ADRs which remain outside the reach of other healthcare providers and in being fundamental to the preservation of the health of patients and of the entire community, with attention to the more vulnerable patients, such as children and the elderly.
PURPOSE: The reporting of suspected adverse drug reactions (ADRs) is starting to become routine to nurses. The aim of this review is to underline the role of clinical and community health nurses in pharmacovigilance and to promote their effective participation in ADR reporting in different countries and for patients of different ages. METHODS: The PubMed, Scopus and ISI Web of Science databases were searched for research articles published between January 1985 and April 2017 using the search items "pharmacovigilance" AND "nurse;" "adverse drug reaction report" AND "nurse;" "community health nurse" AND "adverse drug reaction." RESULTS: A total of 987 articles were identified using our search strategy, of which 180 articles remained over after the removal of duplicate articles. Of these 180 studies, upon full review we identified 24 which met the inclusion/exclusion criteria and included these in our review. ADR reports by clinical nurses in some countries are comparable in quality and number to those submitted by physicians or pharmacists. Data on ADRs reported by community nurses are currently not available. However, numerous publications emphasized the challenges faced by nurses in reporting ADRs and the need to include pharmacovigilance training in both clinical and community health nurse academic education. CONCLUSIONS: Nurses are central actors in pharmacovigilance activities, particularly in identifying ADRs which remain outside the reach of other healthcare providers and in being fundamental to the preservation of the health of patients and of the entire community, with attention to the more vulnerable patients, such as children and the elderly.
Entities:
Keywords:
Adverse drug reaction; Clinical nurse; Community health nurse; National health systems; Pharmacovigilance
Authors: Sílvia Isabel dos Santos Pernas; Maria Teresa Herdeiro; Elena Lopez-Gonzalez; Odete A B da Cruz e Silva; Adolfo Figueiras Journal: Int J Clin Pharm Date: 2012-08-31
Authors: Nibu Parameswaran Nair; Leanne Chalmers; Michael Connolly; Bonnie J Bereznicki; Gregory M Peterson; Colin Curtain; Ronald L Castelino; Luke R Bereznicki Journal: PLoS One Date: 2016-10-31 Impact factor: 3.240
Authors: Emma C Davies; Christopher F Green; Stephen Taylor; Paula R Williamson; David R Mottram; Munir Pirmohamed Journal: PLoS One Date: 2009-02-11 Impact factor: 3.240
Authors: Diana M Rydberg; Lennart Holm; Ida Engqvist; Jessica Fryckstedt; Jonatan D Lindh; Carl-Olav Stiller; Charlotte Asker-Hagelberg Journal: PLoS One Date: 2016-09-13 Impact factor: 3.240
Authors: Stina Mannheimer; Monica Bergqvist; Pia Bastholm-Rahmner; Lars L Gustafsson; Anikó Vég; Katharina Schmidt-Mende Journal: BJGP Open Date: 2022-08-30
Authors: Tim Schutte; Rike van Eekeren; Milan Richir; Jojanneke van Staveren; Eugène van Puijenbroek; Jelle Tichelaar; Michiel van Agtmael Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2017-10-23 Impact factor: 3.000